Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages

International Journal of Molecular Sciences

Volumn 15, Issue 12, 2014, Pages 22960-22977

  Gumulec, Jaromir ^a,b   Fojtu, Michaela ^a   Raudenska, Martina ^a,b   Sztalmachova, Marketa ^a,b   Skotakova, Anna ^a   Vlachova, Jana ^b,c   Skalickova, Sylvie ^b,c   Nejdl, Lukas ^b,c   Kopel, Pavel ^b,c   Knopfova, Lucia ^a   Adam, Vojtech ^b,c   Kizek, Rene ^b,c   Stiborova, Marie ^d   Babula, Petr ^a   Masarik, Michal ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^c MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Apoferritin; Cancer; Cardiotoxicity; Doxorubicin; Encapsulation; Liposome; Modification

Indexed keywords

ANDROGEN RECEPTOR; APOFERRITIN; CHOLESTEROL; DOXORUBICIN; EPIRUBICIN; LIPOSOME; NANOCARRIER; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER;

ARTICLE; CELL COUNT; CELL PROLIFERATION ASSAY; CELL VIABILITY; CONTROLLED STUDY; DIFFERENTIAL PULSE VOLTAMMETRY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; MTT ASSAY; NANOENCAPSULATION; PARTICLE SIZE; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; SPECTROFLUOROMETRY; ZETA POTENTIAL; ANIMAL; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG FORMULATION; HORSE; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOFERRITINS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; HORSES; HUMANS; INHIBITORY CONCENTRATION 50; LIPOSOMES;

EID: 84916918724     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151222960     Document Type: Article

References (38)

1. Blum, R.H.; Carter, S.K. Adriamycin-New anticancer drug with significant clinical activity. Ann. Int. Med. 1974, 80, 249-259.
2. Pommier, Y.; Leo, E.; Zhang, H.L.; Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010, 17, 421-433.
3. Chatterjee, K.; Zhang, J.Q.; Honbo, N.; Karliner, J.S. Doxorubicin cardiomyopathy. Cardiology 2010, 115, 155-162.
4. Obryan, R.M.; Baker, L.H.; Gottlieb, J.E.; Rivkin, S.E.; Balcerzak, S.P.; Grumet, G.N.; Salmon, S.E.; Moon, T.E.; Hoogstraten, B. Dose-response evaluation of adriamycin in human neoplasia. Cancer 1977, 39, 1940-1948.
5. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185-229.
6. Tardi, P.G.; Boman, N.L.; Cullis, P.R. Liposomal doxorubicin. J. Drug Target. 1996, 4, 129-140.
7. Rahman, A.; More, N.; Schein, P.S. Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res. 1982, 42, 1817-1825.
8. Olson, F.; Mayhew, E.; Maslow, D.; Rustum, Y.; Szoka, F. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur. J. Cancer Clin. Oncol. 1982, 18, 167-169.
9. Gabizon, A.; Dagan, A.; Goren, D.; Barenholz, Y.; Fuks, Z. Liposomes as invivo carriers of adriamycin-reduced cardiac uptake and preserved anti-tumor activity in mice. Cancer Res. 1982, 42, 4734-4739.
10. Storm, G.; Roerdink, F.H.; Steerenberg, P.A.; Dejong, W.H.; Crommelin, D.J.A. Influence of lipid-composition on the antitumor-activity exerted by doxorubicin-containing liposomes in a rat solid tumor-model. Cancer Res. 1987, 47, 3366-3372.
11. Balazsovits, J.A.E.; Mayer, L.D.; Bally, M.B.; Cullis, P.R.; McDonell, M.; Ginsberg, R.S.; Falk, R.E. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother. Pharmacol. 1989, 23, 81-86.
12. Mayer, L.D.; Bally, M.B.; Cullis, P.R.; Wilson, S.L.; Emerman, J.T. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the sc115 murine mammary-tumor. Cancer Lett. 1990, 53, 183-190.
13. Dong, H.Q.; Dong, C.Y.; Feng, Y.; Ren, T.B.; Zhang, Z.H.; Li, L.; Li, Y.Y. Engineering of peglayted camptothecin into core-shell nanomicelles for improving solubility, stability and combination delivery. Medchemcomm 2012, 3, 1555-1561.
14. Rahman, A.; Husain, S.R.; Siddiqui, J.; Verma, M.; Agresti, M.; Center, M.; Safa, A.R.; Glazer, R.I. Liposome-mediated modulation of multidrug resistance in human hl-60 leukemia-cells. J. Natl. Cancer Inst. 1992, 84, 1909-1915.
15. Gokhale, P.C.; Radhakrishnan, B.; Husain, S.R.; Abernethy, D.R.; Sacher, R.; Dritschilo, A.; Rahman, A. An improved method of encapsulation of doxorubicin in liposomes: Pharmacological, toxicological and therapeutic evaluation. Br. J. Cancer 1996, 74, 43-48.
16. Oudard, S.; Thierry, A.; Jorgensen, T.J.; Rahman, A. Sensitization of multidrug-resistant colon cancer-cells to doxorubicin encapsulated in liposomes. Cancer Chemother. Pharmacol. 1991, 28, 259-265.
17. Thierry, A.R.; Rahman, A.; Dritschilo, A. A new procedure for the preparation of liposomal doxorubicin: Biological-activity in multidrug-resistant tumor-cells. Cancer Chemother. Pharmacol. 1994, 35, 84-88.
18. Thierry, A.R.; Vige, D.; Coughlin, S.S.; Belli, J.A.; Dritschilo, A.; Rahman, A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. 1993, 7, 572-579.
19. Mickisch, G.H.; Rahman, A.; Pastan, I.; Gottesman, M.M. Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin. J. Natl. Cancer Inst. 1992, 84, 804-805.
20. Yang, Z.; Wang, X.Y.; Diao, H.J.; Zhang, J.F.; Li, H.Y.; Sun, H.Z.; Guo, Z.J. Encapsulation of platinum anticancer drugs by apoferritin. Chem. Commun. 2007, 33, 3453-3455.
21. Meyer, J.S.; Sufrin, G.; Martin, S.A. Proliferative activity of benign human-prostate, prostatic adenocarcinoma and seminal-vesicle evaluated by thymidine labeling. J. Urol. 1982, 128, 1353-1356.
22. Simsek, E.; Kilic, M.A. Magic ferritin: A novel chemotherapeutic encapsulation bullet. J. Magn. Magn. Mater. 2005, 293, 509-513.
23. Tmejova, K.; Hynek, D.; Kopel, P.; Dostalova, S.; Smerkova, K.; Stanisavljevic, M.; Nguyen, H.V.; Nejdl, L.; Vaculovicova, M.; Krizkova, S.; et al. Electrochemical behaviour of doxorubicin encapsulated in apoferritin. Int. J. Electrochem. Sci. 2013, 8, 12658-12671.
24. Yang, Y.W. Towards biocompatible nanovalves based on mesoporous silica nanoparticles. Medchemcomm 2011, 2, 1033-1049.
25. Tseng, Y.L.; Liu, J.J.; Hong, R.L. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: A kinetic and efficacy study. Mol. Pharmacol. 2002, 62, 864-872.
26. Hong, R.L.; Huang, C.J.; Tseng, Y.L.; Pang, V.F.; Chen, S.T.; Liu, J.J.; Chang, F.H. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in c-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial? Clin. Cancer Res. 1999, 5, 3645-3652.
27. Masarik, M.; Gumulec, J.; Hlavna, M.; Sztalmachova, M.; Babula, P.; Raudenska, M.; Pavkova-Goldbergova, M.; Cernei, N.; Sochor, J.; Zitka, O.; et al. Monitoring of the prostate tumour cells redox state and real-time proliferation by novel biophysical techniques and fluorescent staining. Integr. Biol. 2012, 4, 672-684.
28. Komatsu, M.; Waguri, S.; Ueno, T.; Iwata, J.; Murata, S.; Tanida, I.; Ezaki, J.; Mizushima, N.; Ohsumi, Y.; Uchiyama, Y.; et al. Impairment of starvation-induced and constitutive autophagy in atg7-deficient mice. J. Cell Biol. 2005, 169, 425-434.
29. Aitken, R.J.; Whiting, S.; de Iuliis, G.N.; McClymont, S.; Mitchell, L.A.; Baker, M.A. Electrophilic aldehydes generated by sperm metabolism activate mitochondrial reactive oxygen species generation and apoptosis by targeting succinate dehydrogenase. J. Biol. Chem. 2012, 287, 33048-33060.
30. He, C.C.; Klionsky, D.J. Regulation mechanisms and signaling pathways of autophagy. Ann. Rev. Genet. 2009, 43, 67-93.
31. Graeser, R.; Chung, D.E.; Esser, N.; Moor, S.; Schachtele, C.; Unger, C.; Kratz, F. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Int. J. Cancer 2008, 122, 1145-1154.
32. Eom, Y.W.; Kim, M.A.; Park, S.S.; Goo, M.J.; Kwon, H.J.; Sohn, S.; Kim, W.H.; Yoon, G.; Choi, K.S. Two distinct modes of cell death induced by doxorubicin: Apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 2005, 24, 4765-4777.
33. Maejima, Y.; Adachi, S.; Ito, H.; Hirao, K.; Isobe, M. Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 2008, 7, 125-136.
34. Dalby, K.N.; Tekedereli, I.; Lopez-Berestein, G.; Ozpolat, B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010, 6, 322-329.
35. Skjoth, I.H.E.; Issinger, O.G. Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int. J. Oncol. 2006, 28, 217-229.
36. Carruba, G.; Leake, R.E.; Rinaldi, F.; Chalmers, D.; Comito, L.; Sorci, C.; Pavonemacaluso, M.; Castagnetta, L.A.M. Steroid-growth factor interaction in human prostate-cancer. 1. Short-term effects of transforming growth-factors on growth of human prostate-cancer cells. Steroids 1994, 59, 412-420.
37. Herman-Antosiewicz, A.; Xiao, H.; Lew, K.L.; Singh, S.V. Induction of p21 protein protects against sulforaphane-induced mitotic arrest in lncap human prostate cancer cell line. Mol. Cancer Ther. 2007, 6, 1673-1681.
38. Kominkova, M.; Guran, R.; Rodrigo, M.A.M.; Kopel, P.; Blazkova, I.; Chudobova, D.; Nejdl, L.; Heger, Z.; Ruttkay-Nedecky, B.; Zitka, O.; et al. Study of functional qualities of different types of tailored liposomes with encapsulated doxorubicin using electrochemical and optical methods. Int. J. Electrochem. Sci. 2014, 9, 2993-3007.